Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 13, 2020July 13, 2020

Helsinn, Mei Pharma Stop Phase 3 Trial of Pracinostat-Vidaza Combo for AML

News

Helsinn and Mei Pharma have discontinued the Phase 3 trial that was investigating the safety and efficacy of a combination therapy of pracinostat and Vidaza (azacitidine) in newly-diagnosed patients with ... Read more

July 6, 2020July 6, 2020

Venclexta Combo Continues to Help Untreated AML Patients in Phase 3 Trial

News

When given alongside Vidaza (azacitidine), Venclexta (venetoclax) elicits clinically meaningful responses and prolongs survival in untreated acute myeloid leukemia (AML) patients who are not eligible for intense chemotherapy, a Phase 3 ... Read more

June 1, 2020June 1, 2020

FDA OKs Phase 1 Trial of Antibody, IO-202, to Treat Advanced AML and CMML

News

The U.S. Food and Drug Administration (FDA) has agreed to Immune-Onc Therapeutics launching a Phase 1 clinical trial of IO-202, its lead antibody treatment candidate, in patients with advanced acute myeloid leukemia ... Read more

May 14, 2020May 14, 2020

Phase 3 Trial Stops Testing Idasanutlin in AML Patients Undergoing Chemo

News

Roche has removed idasanutlin (RG7388), an investigational anti-cancer agent, from its Phase 3 MIRROS trial that was assessing the effectiveness of the medication when used in combination with chemotherapy in ... Read more

April 30, 2020April 30, 2020

GT Biopharma Completes Dosing of First Patient in Phase 1/2 Trial of GTB-3550

News

GT Biopharma has successfully completed dosing of the first patient participating in its Phase 1/2 clinical trial of GTB-3550 (OXS-3550), the company’s experimental treatment for relapsed or refractory acute myeloid ... Read more

April 23, 2020April 23, 2020

Antibody to Treat AML Showing Safety and Clinical Activity in Early Trial Data

News

APVO436, an investigational therapy for acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), is showing safety and evidence of clinical activity in these patients, according to preliminary data from a ... Read more